Reduced Muscle Strength And Functional Performance In Men With Prostate Cancer Undergoing Androgen Suppression: Cross-Sectional Investigation UroToday.com - It is becoming clearer that androgen suppression therapy (AST) is associated with undesirable side effects.1 While the decline in bone and lean mass following AST has been consistently documented, 2, 3 only scant information exists regarding the impact of testosterone suppression on muscle strength and physical performance.
Source: www.medicalnewstoday.comMabThera Significantly Reduces Risk Of Serious Bleeding In People With Life-Threatening Autoimmune Disorder New data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today, show that people living with a previously untreated bleeding disorder, idiopathic thrombocytopenic purpura (ITP), who received MabThera (rituximab) in combination with standard management were able to prevent bleeding for longer than those receiving standard treatment alone.
Source: www.medicalnewstoday.comNPS RADARhelps Prescribers Navigate Decision-making Prescribers considering use of zoledronic acid (Aclasta) once-yearly infusion in patients who have osteoporosis will need to weigh up the possible benefits against the relative lack of experience with this drug in osteoporosis. This month's NPS RADAR review of the newly PBS-listed drug provides information to help prescribers' decision-making and to counsel patients.
Source: www.medicalnewstoday.comUpdated Standards To Reduce Metal Contaminants In Prescription Drugs Prescription medicines in the United States could soon have lower levels of potentially harmful metals, as the organization that sets drug standards develops new limits for impurities like mercury, arsenic, and lead, according to an article scheduled for the December 8 issue of Chemical & Engineering News, ACS' weekly news magazine.
Source: www.medicalnewstoday.comProfessor Jan Vermorken Is The New Editor-in-chief Of Annals Of Oncology Professor Jan B. Vermorken, an internationally respected medical oncologist based at Antwerp University Hospital (Edegem, Belgium), has been appointed to be the next editor-in-chief of the cancer journal, Annals of Oncology.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
